WID Easy swab test (Pilot)

What this is

Airedale NHS Foundation Trust intends to procure a provider to implement the WID-easy endometrial cancer test on a pilot basis. The WID-easy test is a non-invasive, DNA methylation-based diagnostic for detecting endometrial cancer in women with Abnormal Uterine Bleeding. The contract covers supply of the required equipment, test processing, and provision of results, running as a 3-6 month trial from 12/04/2026. This is a Provider Selection Regime (PSR) intended approach notice awarded via the 'most suitable provider' process.

Key points

• PSR most suitable provider process (not PCR 2015)
• Estimated value £30,000-£40,000
• 3-6 month trial from 12/04/2026

Who can bid

Providers able to supply the WID-easy endometrial cancer testing equipment, process tests and return results. Awarded under the Provider Selection Regime (PSR) most suitable provider process; Public Contracts Regulations 2015 do not apply.

How it is scored

Selection via the PSR 'most suitable provider' process; no explicit quality/price weightings published.

Money

Contract expected to be valued between £30,000 and £40,000.

How to submit

Intended approach notice; providers may express interest in being considered as the most suitable provider via the Find a Tender notice.

Contract period

Agreed trial period of 3-6 months, to run from 12/04/2026.

Classification

CPV 85111800 — Pathology services EnglandYorkshire and the HumberBradford